Forest Laboratories was a company in the pharmaceutical industry incorporated in Delaware, with its principal office in New York City.

[3] In 1984, the company acquired O'Neal Jones & Feldman for $8.8 million after a federal investigation resulted in one of its drugs being recalled.

[6] On August 16, 2002, the company received approval from the Food and Drug Administration for Lexapro (Escitalopram), an updated version of Celexa.

Some of the products Forest Laboratories marketed with its partners included: In September 2010, the company agreed to pay $313 million to resolve allegations of civil and criminal liability relating to felony, obstruction of justice, and the illegal distribution and promotion of pharmaceuticals, charges to which it pled guilty.

[11][12][13] Forest Laboratories has been accused of using unlawful deals to prevent generic versions of its Alzheimer's disease drug Namenda from entering the market.